Tags

Type your tag names separated by a space and hit enter

Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy.
Diabet Med. 2007 Jun; 24(6):635-42.DM

Abstract

AIMS

To compare glycaemic control and risk of hypoglycaemia of twice-daily insulin detemir with once-daily insulin glargine in subjects with Type 1 diabetes.

METHODS

In this 26-week, multicentre, open-label, parallel-group trial, 320 subjects with Type 1 diabetes received either insulin detemir twice daily or insulin glargine once daily. each in combination with premeal insulin aspart.

RESULTS

After 26 weeks, HbA(1c) had decreased from 8.8 to 8.2% in the insulin detemir group and from 8.7 to 8.2% in the insulin glargine group. Home-measured fasting plasma glucose (PG) was lower with insulin glargine than with insulin detemir (7.0 vs. 7.7 mmol/l, P < 0.001). The overall shape of the home-measured nine-point PG profiles was comparable between treatments (P = 0.125). Overall, there was no significant difference in within-subject variation in PG (P = 0.437). Within-subject variation in predinner PG was lower with insulin detemir than with insulin glargine (P < 0.05). The overall risk of hypoglycaemia was similar with no differences in confirmed hypoglycaemia. However, the risk of severe and nocturnal hypoglycaemia was 72% and 32%, respectively, lower with insulin detemir than with insulin glargine (P < 0.05). Body weight gain was not significantly different comparing insulin detemir and insulin glargine (0.52 kg vs. 0.96 kg, P = 0.193).

CONCLUSIONS

Treatment with twice-daily insulin detemir or once-daily insulin glargine, each in combination with insulin aspart, resulted in similar glycaemic control. The overall risk of hypoglycaemia was comparable, whereas the risks of both severe and nocturnal hypoglycaemia were significantly lower with insulin detemir.

Authors+Show Affiliations

Leopold Auenbrugger Medical University, Graz, Austria. thomas.pieber@meduni-graz.atNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

17381500

Citation

Pieber, T R., et al. "Comparison of Insulin Detemir and Insulin Glargine in Subjects With Type 1 Diabetes Using Intensive Insulin Therapy." Diabetic Medicine : a Journal of the British Diabetic Association, vol. 24, no. 6, 2007, pp. 635-42.
Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med. 2007;24(6):635-42.
Pieber, T. R., Treichel, H. C., Hompesch, B., Philotheou, A., Mordhorst, L., Gall, M. A., & Robertson, L. I. (2007). Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabetic Medicine : a Journal of the British Diabetic Association, 24(6), 635-42.
Pieber TR, et al. Comparison of Insulin Detemir and Insulin Glargine in Subjects With Type 1 Diabetes Using Intensive Insulin Therapy. Diabet Med. 2007;24(6):635-42. PubMed PMID: 17381500.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. AU - Pieber,T R, AU - Treichel,H-C, AU - Hompesch,B, AU - Philotheou,A, AU - Mordhorst,L, AU - Gall,M-A, AU - Robertson,L I, Y1 - 2007/03/22/ PY - 2007/3/27/pubmed PY - 2007/9/28/medline PY - 2007/3/27/entrez SP - 635 EP - 42 JF - Diabetic medicine : a journal of the British Diabetic Association JO - Diabet Med VL - 24 IS - 6 N2 - AIMS: To compare glycaemic control and risk of hypoglycaemia of twice-daily insulin detemir with once-daily insulin glargine in subjects with Type 1 diabetes. METHODS: In this 26-week, multicentre, open-label, parallel-group trial, 320 subjects with Type 1 diabetes received either insulin detemir twice daily or insulin glargine once daily. each in combination with premeal insulin aspart. RESULTS: After 26 weeks, HbA(1c) had decreased from 8.8 to 8.2% in the insulin detemir group and from 8.7 to 8.2% in the insulin glargine group. Home-measured fasting plasma glucose (PG) was lower with insulin glargine than with insulin detemir (7.0 vs. 7.7 mmol/l, P < 0.001). The overall shape of the home-measured nine-point PG profiles was comparable between treatments (P = 0.125). Overall, there was no significant difference in within-subject variation in PG (P = 0.437). Within-subject variation in predinner PG was lower with insulin detemir than with insulin glargine (P < 0.05). The overall risk of hypoglycaemia was similar with no differences in confirmed hypoglycaemia. However, the risk of severe and nocturnal hypoglycaemia was 72% and 32%, respectively, lower with insulin detemir than with insulin glargine (P < 0.05). Body weight gain was not significantly different comparing insulin detemir and insulin glargine (0.52 kg vs. 0.96 kg, P = 0.193). CONCLUSIONS: Treatment with twice-daily insulin detemir or once-daily insulin glargine, each in combination with insulin aspart, resulted in similar glycaemic control. The overall risk of hypoglycaemia was comparable, whereas the risks of both severe and nocturnal hypoglycaemia were significantly lower with insulin detemir. SN - 0742-3071 UR - https://www.unboundmedicine.com/medline/citation/17381500/Comparison_of_insulin_detemir_and_insulin_glargine_in_subjects_with_Type_1_diabetes_using_intensive_insulin_therapy_ L2 - https://doi.org/10.1111/j.1464-5491.2007.02113.x DB - PRIME DP - Unbound Medicine ER -